Back to Search Start Over

Consistent cardiovascular (CV) benefit of empagliflozin over the spectrum of CV risk factor control in EMPA-REG OUTCOME.

Authors :
Inzucchi, S.E.
Khunti, K.
Fitchett, D.H.
Wanner, C.
Mattheus, M.
George, J.T.
Ofstad, A.P.
Zinman, B.
Source :
Metabolism: Clinical & Experimental; Mar2020 Supplement, Vol. 104, pN.PAG-N.PAG, 1p
Publication Year :
2020

Subjects

Subjects :
EMPAGLIFLOZIN
CARDIOVASCULAR diseases risk factors

Details

Language :
English
ISSN :
00260495
Volume :
104
Database :
Supplemental Index
Journal :
Metabolism: Clinical & Experimental
Publication Type :
Academic Journal
Accession number :
142044574
Full Text :
https://doi.org/10.1016/j.metabol.2019.12.071
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details